Vir Biotechnology (NASDAQ:VIR) Shares Cross Above 50 Day Moving Average - Should You Sell?

Key Points

• Vir Biotechnology shares rose above their 50-day moving average of $11.03, reaching as high as $12.45 and last trading at $12.21.
• Analyst sentiment improved: Needham raised its price target to $20 and maintained a Buy rating, while Zacks upgraded the stock from Strong Sell to Hold; the consensus rating is Moderate Buy with a $22.14 average target.
• Q3 earnings beat expectations, with a loss of $0.57 per share versus estimates of $0.75–$0.80, but revenue missed sharply at negative $0.19 million. Investors are also watching for topline Phase 3 ECLIPSE 1 results, expected to be presented at AASLD’s 2026 meeting.

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $11.03 and traded as high as $12.45. Vir Biotechnology shares last traded at $12.21, with a volume of 1,887,037 shares changing hands.

Key Headlines Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Analyst sentiment improved: Needham raised its price target to $20 from $18 and maintained a Buy rating. Zacks Research also upgraded VIR from Strong Sell to Hold, reducing a bearish signal. Needham rating Zacks rating
• Positive Sentiment: Key clinical catalyst ahead: Vir plans to present topline Phase 3 ECLIPSE 1 results for elebsiran and tobevibart in chronic hepatitis delta at AASLD’s 2026 liver meeting. Positive data could be a meaningful catalyst, though the outcome is uncertain. AASLD data presentation
• Positive Sentiment: Cash runway extends into the second half of 2028, giving the company additional time to advance its pipeline and reach development milestones. Cash runway update
• Neutral Sentiment: Q3 loss beat expectations: Vir reported a loss of $0.57 per share, narrower than analysts’ expected loss of about $0.75–$0.80 and the $1.17 loss a year earlier. Q3 results
• Neutral Sentiment: An executive sold a small number of shares under a pre-arranged plan to cover tax withholding on vested equity awards; the stated purpose makes this less indicative of a change in outlook. SEC filing
• Negative Sentiment: Revenue missed sharply: Q3 revenue was negative $0.19 million versus analysts’ estimate of $0.98 million, and was down 178.3% year over year, tempering the earnings beat. Revenue results

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Needham & Company LLC upped their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Thursday. Zacks Research upgraded Vir Biotechnology from a "strong sell" rating to a "hold" rating in a report on Wednesday. Wall Street Zen raised Vir Biotechnology from a "hold" rating to a "buy" rating in a report on Saturday. Raymond James Financial reiterated a "strong-buy" rating on shares of Vir Biotechnology in a report on Monday, September 28th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Vir Biotechnology in a research note on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $22.14.

Vir Biotechnology Price Performance

The stock has a market capitalization of $2.07 billion, a P/E ratio of -9.69 and a beta of 1.70. The stock's fifty day moving average is $11.03 and its two-hundred day moving average is $9.61.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.18. The company had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.98 million. The business's quarterly revenue was down 178.3% compared to the same quarter last year. During the same period last year, the business earned ($1.17) EPS. Analysts expect that Vir Biotechnology, Inc. will post -1.84 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Vanina de Verneuil sold 2,407 shares of the stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $11.10, for a total value of $26,717.70. Following the transaction, the executive vice president directly owned 110,193 shares of the company's stock, valued at $1,223,142.30. This represents a 2.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.90% of the company's stock.

Institutional Investors Weigh In On Vir Biotechnology

Large investors have recently added to or reduced their stakes in the stock. Fiduciary Financial Advisors purchased a new position in Vir Biotechnology in the second quarter valued at $29,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Vir Biotechnology in the 3rd quarter valued at about $97,000. Caxton Associates LLP bought a new position in Vir Biotechnology in the 1st quarter worth approximately $112,000. Amundi boosted its holdings in shares of Vir Biotechnology by 52.8% during the 1st quarter. Amundi now owns 15,315 shares of the company's stock valued at $137,000 after buying an additional 5,294 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in Vir Biotechnology by 223.1% during the first quarter. Royal Bank of Canada now owns 15,355 shares of the company's stock valued at $138,000 after purchasing an additional 10,603 shares during the last quarter. 65.32% of the stock is owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir's research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.